ARAY - Accuray Incorporated

NasdaqGS - NasdaqGS Real-time price. Currency in USD
4.00
+0.05 (+1.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close3.95
Open3.95
Bid3.85 x 500
Ask4.10 x 3500
Day's range3.90 - 4.00
52-week range3.60 - 6.15
Volume315,214
Avg. volume525,623
Market cap342.552M
Beta2.58
PE ratio (TTM)N/A
EPS (TTM)-0.34
Earnings date16 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.20
Trade prices are not sourced from all markets
  • Accuray's Radixact Gets AERB Nod in India, Prospects Solid
    Zacks29 days ago

    Accuray's Radixact Gets AERB Nod in India, Prospects Solid

    The Atomic Energy Regulatory Board (AERB) approves Accuray's (ARAY) Radixact X9 in India; exposes the company to AI and Mechatronic trends.

  • At US$04.325, Is It Time To Buy Accuray Incorporated (NASDAQ:ARAY)?
    Simply Wall St.last month

    At US$04.325, Is It Time To Buy Accuray Incorporated (NASDAQ:ARAY)?

    Accuray Incorporated (NASDAQ:ARAY), a medical equipment company based in United States, received a lot of attention from a substantial price movement on the NasdaqGS over the last few months, increasingRead More...

  • New Strong Sell Stocks for June 11th
    Zackslast month

    New Strong Sell Stocks for June 11th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Here's Why You Should Sell Accuray (ARAY) Stock Right Now
    Zacks2 months ago

    Here's Why You Should Sell Accuray (ARAY) Stock Right Now

    Regulatory issues regarding Onrad, intense competition in the radiation oncology market and unfavorable foreign exchange rate are significant challenges for Accuray (ARAY).

  • New Strong Sell Stocks for June 4th
    Zacks2 months ago

    New Strong Sell Stocks for June 4th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Accuray (ARAY) Down 13.7% Since Earnings Report: Can It Rebound?
    Zacks2 months ago

    Accuray (ARAY) Down 13.7% Since Earnings Report: Can It Rebound?

    Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Why Accuray, Cincinnati Bell, and Chesapeake Energy Slumped Today
    Motley Fool2 months ago

    Why Accuray, Cincinnati Bell, and Chesapeake Energy Slumped Today

    Find out which company dealt with weak earnings.

  • New Strong Sell Stocks for May 23rd
    Zacks2 months ago

    New Strong Sell Stocks for May 23rd

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • New Strong Sell Stocks for May 17th
    Zacks2 months ago

    New Strong Sell Stocks for May 17th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • PR Newswire2 months ago

    Accuray Unveils New Company Website Reflecting Industry-Leading Patient-First Cancer Treatment Innovation and Care

    Accuray Incorporated (Nasdaq:ARAY) announced today the unveiling of a new corporate website that reflects the company's evolution and leadership in patient-first cancer treatment innovations. The fully redesigned, modern site puts critical disease and treatment information at the fingertips of website visitors, highlights the unique features and capabilities that set the company's radiotherapy tools-including the CyberKnife®, TomoTherapy® and Radixact® Systems-apart, and will serve as home base for details on future breakthroughs. As part of this, we continually introduce cancer treatment breakthroughs that help our customers improve clinical and economic outcomes.

  • Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top
    Zacks3 months ago

    Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top

    Radixact System and major software overhaul drive Accuray (ARAY) in Q3.

  • Associated Press3 months ago

    Accuray: Fiscal 3Q Earnings Snapshot

    The Sunnyvale, California-based company said it had a loss of 10 cents per share. The radiation oncology company posted revenue of $99.8 million in the period. Accuray expects full-year revenue in the ...

  • PR Newswire3 months ago

    Accuray to Bring Patient-First Cancer Treatment Innovations to ESTRO 37

    Accuray Incorporated (Nasdaq:ARAY) announced today it will be showcasing the benefits of its radiotherapy systems and software solutions at the 37th annual European Society for Radiotherapy and Oncology (ESTRO) meeting in Barcelona, Spain. The meeting, to be held April 20-24, 2018, will attract more than 3,000 radiation oncology professionals who will gather to gain information and insights on the latest developments in radiation therapy. Accuray will be in attendance at booth #1700, sharing information on new treatment approaches and providing opportunities for conversations about how the company's innovative CyberKnife® and Radixact® Systems, and advanced software solutions, can help improve the radiation therapy treatment experience for clinicians and their patients.

  • Accuray Radixact Picked by India's Apollo for Cancer Treatment
    Zacks4 months ago

    Accuray Radixact Picked by India's Apollo for Cancer Treatment

    Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.

  • Accuray's CyberKnife Treats First Patient at Erasmus MC
    Zacks4 months ago

    Accuray's CyberKnife Treats First Patient at Erasmus MC

    Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.

  • Accuray Banks on Acquisition & Partnership Amid Competition
    Zacks4 months ago

    Accuray Banks on Acquisition & Partnership Amid Competition

    Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.

  • PR Newswire4 months ago

    Erasmus MC Completes First Step in the Evolution of Online Adaptive Radiation Therapy With the CyberKnife® System

    Accuray Incorporated (NASDAQ:ARAY) and Erasmus MC, the largest university medical center in the Netherlands, announced today that the first patient has been successfully treated using an online-adaptive (OA) approach together with the CyberKnife® System. The patient, treated for oligometastases in the pelvic region, is part of a new clinical trial conducted at Erasmus MC evaluating OA stereotactic body radiation therapy (SBRT) delivered by the CyberKnife platform. "At Erasmus MC our goal is to use innovative approaches to provide customized, effective treatments that help extend or improve the quality of life of people diagnosed with cancer, regardless of the stage of their cancer diagnosis," said J.J. Nuyttens, MD, PhD, radiation oncologist, department of radiation oncology, Erasmus MC.

  • Accuray Gains on Radixact Unit, Solid Geographical Foothold
    Zacks4 months ago

    Accuray Gains on Radixact Unit, Solid Geographical Foothold

    Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).

  • Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session
    Zacks4 months ago

    Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session

    The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.

  • How Accuray Has Performed Financially
    Market Realist5 months ago

    How Accuray Has Performed Financially

    In 2Q18, Accuray’s (ARAY) net revenues were $100.3 million compared with $87.5 million in 2Q17. Its total revenues come from product sales and services provided. Product sales grew from $35.3 million in 2Q17 to $47.1 million in 2Q18.

  • How Much Is Accuray’s Target Market Expected to Grow?
    Market Realist5 months ago

    How Much Is Accuray’s Target Market Expected to Grow?

    To increase physician adoption and patient awareness of its systems, Accuray (ARAY) holds and sponsors symposia and educational meetings and educates clinicians about its systems. Accuray focuses on innovation through clinical development and collaboration and seeks constructive feedback from its system users to enhance the company’s product offerings. Accuray endeavors to expand sales in international markets. According to the World Health Organization (or WHO), cancer is the second-leading cause of death worldwide.

  • What Analysts Recommend for Accuray in February 2018
    Market Realist5 months ago

    What Analysts Recommend for Accuray in February 2018

    Accuray (ARAY) designs, develops, and commercializes advanced radiosurgery and radiation therapy systems for the treatment of tumors. Accuray’s technologies include the CyberKnife and Tomo Theory systems, which deliver radiosurgery, stereotactic body radiation therapy, and adaptive radiation therapy. In February 2018, three of the seven analysts covering Accuray have given the stock a “buy” or higher rating.

  • A Look at Accuray’s Therapy Systems
    Market Realist5 months ago

    A Look at Accuray’s Therapy Systems

    Accuray’s (ARAY) CyberKnife systems are robotic systems that treat cancerous tumors through the delivery of radiosurgery. Accuray’s Tomo therapy systems are versatile radiation therapy systems that are used for treating a wide range of cancer types. Based on a CT scanner platform, the Tomo therapy systems provide continuous delivery of radiation from 360 degrees around the patient or from beam angles specified by the clinician.

  • Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?
    Zacks5 months ago

    Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?

    Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • PR Newswire5 months ago

    Accuray's European AERO Academy Meeting: Innovation and Safety in the Field of Advanced Radiotherapy - Patients Come First

    Accuray Incorporated (NASDAQ:ARAY) announced today highlights from its 2018 European AERO™ (Accuray Exchange in Radiation Oncology) Academy conference held in Lisbon, Portugal on January 26th and 27th. "Accuray is firmly committed to providing our customers with access to clinical thought leadership and forums that encourage treatment innovation. The AERO Academy events, both in the US and in Europe, are a driving force behind our patient-first philosophy," said Joshua H. Levine, President and Chief Executive Officer at Accuray.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes